Pre-market hot trades in US stocks: Indaptus Therapeutics pre-market down 17.20%; Callan Jmb pre-market down 16.67%

Popular Pre-Market Trades in US Stocks Indaptus Therapeutics, down 17.20% in pre-market, has no significant recent news. Trading is active with clear capital flow, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Callan Jmb, down 16.67% in pre-market, has no significant recent news. Trading is active with clear capital flow, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Top Gainers in Pre-Market US Stocks INVO Fertility, up 418.22% in pre-market, has no significant recent news. Trading is active with clear capital flow, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Icon Energy, up 128.35% in pre-market, has no significant recent news. Trading is active with clear capital flow, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. RAPT, up 63.48% in pre-market. Based on recent key news: On January 20, GSK announced the acquisition of RAPT Therapeutics for $2.2 billion, driving RAPT's stock price up. GSK will acquire RAPT at a price of $58 per share, which represents a significant premium over its previous trading day's closing price. This acquisition will give GSK global rights to RAPT's experimental food allergy drug ozureprubart, excluding mainland China, Macau, Taiwan, and Hong Kong. This move expands GSK's respiratory, immunology, and inflammation product lines, resulting in a roughly 65% increase in RAPT's stock price; On January 20, GSK's Chief Scientific Officer Tony Wood stated that ozureprubart is expected to become a best-in-class treatment, providing sustained protection every 12 weeks. This drug is currently in Phase II trials, with single-agent study results expected in 2027. This news further bolstered market confidence in RAPT, driving the stock price up; On January 20, RAPT's CEO Brian Wong stated that the deal with GSK provides an attractive path forward for its projects. RAPT's losses decreased in the first nine months of 2025, with significant reductions in R&D expenses, and these financial improvements also supported the stock price increase. The biotechnology industry is experiencing active merger and acquisition activities, with clear capital inflows